Austedo XR (deutetrabenazine extended release) / Teva - LARVOL DELTA

Real-world Persistence in Patients with Tardive Dyskinesia: A Comparative Study of Valbenazine and Deutetrabenazine XR (AAN 2026) - "Objective: Evaluate persistence outcomes among matched deutetrabenazine-extended-release (XR) and valbenazine cohorts.Background: Vesicular monoamine transporter 2 inhibitors (VMAT2is), valbenazine and deutetrabenazine-XR, are the only once-daily, FDA-approved, guideline-recommended treatments for tardive dyskinesia (TD). To our knowledge, this is the first study comparing persistence between valbenazine and deutetrabenazine-XR in a real-world setting. Results showed valbenazine had greater persistence and less switching vs deutetrabenazine-XR. Higher persistence rates with valbenazine were seen after the first month and were sustained through the 6-month follow-up."

Clinical • Real-world • Real-world evidence • CNS Disorders • Huntington's Disease • Movement Disorders

Patient Experience With Once-daily Deutetrabenazine Extended-release Tablets for the Treatment of Tardive Dyskinesia in Individuals With Prior Valbenazine Use (AAN 2026) - "Most participants with TD who reported previously using valbenazine and those who initiated deutetrabenazine QD de novo reported improvements in their extra movements and overall satisfaction with deutetrabenazine QD."

Clinical • Genetic Disorders • Huntington's Disease • Movement Disorders

Medicare announces price cuts for…prescription drugs… (MSN News) - "Here are the negotiated prices for the drugs, based on a 30-day supply, compared to the 2024 list price:...(i) Otezla, a psoriatic arthritis drug: $1,650, down from $4,722...; (ii) Austedo and Austedo XR, for Huntington’s disease: $4,093, down from $6,623."

Commercial • Huntington's Disease • Psoriatic Arthritis

Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington's disease. (PubMed, Expert Rev Neurother) - "Due to the lack of comparative clinical trial data, no evidence-based recommendation about choice of VMAT2 inhibitor or switching between VMAT2 inhibitors can be made about best practice. Ultimately, QD dosing may offer the chance of improved medication adherence, an important consideration in patients with complex treatment regimens and/or patients with cognitive decline."

Journal • Review • ADHD (Impulsive Aggression) • Huntington's Disease • Movement Disorders

Teva Announces AUSTEDO XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) (Businesswire) - "Teva Pharmaceuticals...today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO XR as a one pill, once-daily treatment option, now with four new tablet strengths (30, 36, 42, 48 mg) indicated in adults for TD and HD chorea."

FDA approval • CNS Disorders • Huntington's Disease

AUSTEDO XR: Clinical Considerations Across a Patient’s Journey with TD (APA 2023) - "Supported by TEVA"

Clinical

AUSTEDO XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO, Now Available in the U.S. (Businesswire) - "Teva Pharmaceuticals...today announced that once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets are now available for adults in the United States in 6 mg, 12 mg and 24 mg tablet strengths. AUSTEDO XR was recently approved by the U.S. Food and Drug Administration (FDA) for adults living with tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). AUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor with 3-year data that is indicated in adults for both TD and HD chorea indications....Approximately 90% of patients with insurance coverage are expected to pay $10 or less with financial assistance offerings."

Commercial • Launch US • Genetic Disorders • Huntington's Disease

"$TEVA AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S. https://t.co/9VQrBzOXxR" (@stock_titan)

Teva to Present New Data on Once-Daily AUSTEDO XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting (Businesswire) - "Teva Pharmaceuticals...today announced six poster abstracts across its neurology portfolio will be presented at the American Academy of Neurology (AAN) Annual Meeting on April 22-27, 2023. Abstracts include data for AUSTEDO (deutetrabenazine) tablets, as well as once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets....Additional abstracts from the Enroll-HD Global Registry and AJOVY® (fremanezumab-vfrm) will also be presented."

Clinical data • Observational data • Real-world effectiveness • CNS Disorders • Genetic Disorders • Huntington's Disease • Migraine • Pain